Betsy Laplant
Overview
Explore the profile of Betsy Laplant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luskin M, Yin J, Lozanski G, Curran E, Malnassy G, Mrozek K, et al.
Cancer
. 2025 Feb;
131(4):e35750.
PMID: 39916320
Background: Acute lymphoblastic leukemia (ALL) in adults is aggressive, with long-term outcomes impacted by treatment resistance and toxicity. CD52 is expressed in most cases of B- and T-lineage ALL. Alemtuzumab,...
2.
Abdallah N, Dizona P, Kumar A, Laplant B, Menser T, Schaeferle G, et al.
Blood Adv
. 2024 Dec;
9(5):1137-1146.
PMID: 39693516
Several tools have been proposed for assessing frailty in multiple myeloma (MM), but most are based on clinical trial data sets. There are also limited data on the association between...
3.
Rutherford S, Yin J, Pederson L, Perez Burbano G, Laplant B, Shadman M, et al.
J Clin Oncol
. 2022 Jul;
41(2):336-342.
PMID: 35787017
Purpose: Bone marrow biopsies (BMB) are performed before/after therapy to confirm complete response (CR) in patients with lymphoma on clinical trials. We sought to establish whether BMB add value in...
4.
Desai S, Pederson L, Laplant B, Mwangi R, Maurer M, Young J, et al.
Blood Cancer J
. 2022 May;
12(5):78.
PMID: 35504884
Studies evaluating Positron Emission Tomography scan after 2 cycles of chemotherapy (PET2) in newly diagnosed diffuse large B cell lymphoma (DLBCL) are heterogeneous in patient characteristics, treatments and have conflicting...
5.
Desai S, Laplant B, Macon W, King R, Wang Y, Inwards D, et al.
Blood Cancer J
. 2021 Sep;
11(9):160.
PMID: 34564694
Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide has response rates of 45% in relapsed transformed DLBCL....
6.
Wudhikarn K, Padrnos L, Lasho T, Laplant B, Kumar S, Dispenzieri A, et al.
Am J Hematol
. 2021 Feb;
96(5):E157-E162.
PMID: 33580975
No abstract available.
7.
Hwang S, Higgins A, Castillo Almeida N, Laplant B, Maurer M, Ansell S, et al.
Leuk Lymphoma
. 2020 Oct;
62(1):247-251.
PMID: 33021136
No abstract available.
8.
Cheson B, Bartlett N, Laplant B, Lee H, Advani R, Christian B, et al.
Lancet Haematol
. 2020 Oct;
7(11):e808-e815.
PMID: 33010817
Background: Hodgkin lymphoma is potentially curable. However, 15-35% of older patients (ie, >60 years) have a lower response rate, worse survival outcomes, and greater toxicity than younger patients. Brentuximab vedotin...
9.
Warsame R, Laplant B, Kumar S, Laumann K, Perez Burbano G, Buadi F, et al.
Blood Cancer J
. 2020 Jan;
10(1):4.
PMID: 31913261
Rarity of light-chain amyloidosis (AL) makes randomized studies challenging. We pooled three phase II studies of immunomodulatory drugs (IMiDs) to update survival, toxicity, and assess new response/progression criteria. Studies included...
10.
Yin J, Laplant B, Uy G, Marcucci G, Blum W, Larson R, et al.
Blood Adv
. 2019 Jun;
3(11):1714-1721.
PMID: 31171508
Event-free survival (EFS) is controversial as an end point for speeding approvals in newly diagnosed acute myeloid leukemia (AML). We aimed to examine the robustness of EFS, specifically timing of...